Achiko AG – Publication of the annual report and annual financial statements 2021 is due by June 10, 2022

Achiko AG / Keyword(s): Miscellaneous
Achiko AG – Publication of the annual report and annual financial statements 2021 is due by June 10, 2022

06-June-2022 / 11:05 CET/CEST
Publication of an ad hoc announcement pursuant to Art. 53LR
The issuer is solely responsible for the content of this announcement.

Achiko AG – Publication of the annual report and annual financial statements 2021 is due by June 10, 2022

Zurich, June 6, 2022: Ad hoc announcement pursuant to Art. 53LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) announces that Achiko will publish its annual report and annual financial statements for the year 2021 on June 10, 2022 at the latest. As a SIX-listed company, Achiko is required to publish its annual report, as well as annual financial statements, within four months of the balance sheet date. Due to the Covid-19 pandemic, recruitment and training under difficult conditions following the measures taken by several countries required a great deal of management capacity. Accordingly, the publication of the 2021 annual report, together with the annual financial statements and the audit report, will take place in the month of June 2022. Achiko has filed an exemption request with SIX Exchange Regulation (SER) regarding the publication of the 2021 annual report and annual accounts. On April 28, 2022, SER granted Achiko the requested extension. Achiko filed a second extension request with SER regarding the publication of the 2021 Annual Report and Annual Financial Statements. On May 30, 2022, SER granted Achiko the second extension. Achiko filed a third extension request with SER regarding the publication of the 2021 Annual Report and Annual Financial Statements. On June 3, 2022, SER granted Achiko the third extension. The delay is based on previously announced elements, including the continuity of operations in the second half of the fiscal year due to the COVID 19 pandemic and the higher than expected manual administrative workload, in particular with regard to the documentation of auditory reconciliation.

As required by SER, Achiko hereby reprints par. I of the respective decision of the SER:

“Achiko’s (issuer) waiver request dated May 30, 2022 requesting a third extension of the deadline for publishing its 2021 annual report and filing this report with SIX Exchange Regulation AG until June 10, 2022 at later is granted with the following reservation ( lit. a) and under the following conditions (lit. b):

a. SIX Exchange Regulation AG reserves the right to suspend trading in the issuer’s registered shares if its annual report 2021 is not published in accordance with the provisions on ad hoc publicity (Art. 53 of the Listing Regulations [LR] in connection with the directive on event advertising [DAH])

b. Achiko is required to publish a notice in accordance with the provisions on event advertising (art. 53 LR in relation to the DAH) concerning this decision until Monday, June 6, 2022, 11:59 p.m. CET, at the latest. The notice must contain:

– the reproduction without modification of the wording of para. I. of this decision, placed in first place;

– the reasons for the Issuer’s request for a third extension of the deadline for publishing its 2021 annual report and filing this report with SIX Exchange Regulation AG.”

The date of the next annual general meeting will be announced in due course, once the Company has published its annual report and annual financial statements for the year 2021.

ABOUT ACHIKO AG
Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) develops breakthrough diagnostic solutions that put people first. The company’s flagship product is a fast and reliable Covid-19 test with a companion app offering a user-friendly digital health passport. The test and companion app were launched in Indonesia in mid-2021 and an application for CE mark approval in Europe will be submitted in 2022.

Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameXMT and complementary health apps through its digital mobile health technology division, Teman SehatMT. AptameX DNA aptamer assays can be rapidly chemically synthesized, are cost effective and have broad potential for the diagnosis of several diseases. Leveraging AptameX and Teman Sehat, Achiko aims to provide rapid, accurate and affordable diagnostic tests for a range of pathogenic diseases and therapeutic indications in the rapidly evolving field of healthcare diagnostics.

Based in Zurich, Achiko has offices in Jakarta and staff worldwide.

Media contacts:

ACHIKO S.A.
Investor Relations
E: [email protected]

Switzerland and the world
Marcus Balogh
Farner Consulting Ltd.
E: [email protected]
Such. : +41 44 266 67 67

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements regarding Achiko AG and its business. These statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Achiko AG to be materially different from any future results, performance or achievements expressed or implied. -understood by these forward-looking statements. statements. Achiko AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Jacob L. Thornton